Biomedical subjects

A A Tovar

Publications and source records attributed to A A Tovar.

6 recordsLinked to original sources

PubMed2001

Propagation of flat-topped multi-Gaussian laser beams.

The multi-Gaussian beam shape is proposed as a model for aperture functions and laser beam profiles that have a nearly flat top but whose sides decrease continuously. Beams and apertures of this type represent a simple, elegant, and intuitive alternative to super-Gaussian beams, which are important in a number of applications such as laser resonator design. Analytical formulas are developed for the propagation of these beams through free space and optical systems representable by ABCD matrices.

Journal Article↗

PubMed2000

Propagation of Laguerre-Bessel-Gaussian beams.

New exact solutions to the paraxial wave equation are obtained in the form of a product of Laguerre polynomials, Bessel functions, and Gaussian functions. In the limit of large Laguerre-Gaussian beam size, the Bessel factor dominates and the solution sets reduce to the modes of closed resonators, hollow metal waveguides, and dielectric waveguides. In the opposite limit the solutions reduce to Laguerre-Gaussian modes of open resonators and graded-index waveguides. These solutions are valid for electromagnetic waves traveling through free space, and they are valid for propagation through circularly symmetric optical systems representable by ABCD matrices as well. An interesting feature of the new solution set is the existence of three mode indices, where only two are required for an orthogonal expansion. As an example, Laguerre-Gaussian beam propagation through an optical system that contains a Bessel-like amplitude filter is discussed.

Journal Article↗

PubMed1998

Production and propagation of Hermite-sinusoidal-Gaussian laser beams.

Hermite-sinusoidal-Gaussian solutions to the wave equation have recently been obtained. In the limit of large Hermite-Gaussian beam size, the sinusoidal factors are dominant and reduce to the conventional modes of a rectangular waveguide. In the opposite limit the beams reduce to the familiar Hermite-Gaussian form. The propagation of these beams is examined in detail, and resonators are designed that will produce them. As an example, a special resonator is designed to produce hyperbolic-sine-Gaussian beams. This ring resonator contains a hyperbolic-cosine-Gaussian apodized aperture. The beam mode has finite energy and is perturbation stable.

Lasers↗

PubMed1994

Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis.

The efficacy and toxicity of two regimens of antimony, 28 and 40 days of 20 mg of antimony/kg/day, were compared in the treatment of culture-positive mucosal leishmaniasis involving more than one anatomic site. Forty consecutive eligible Peruvians with infiltrative or ulcerative mucosal disease of the lips, nose, palate-uvula-pharynx, or larynx-epiglottis were randomized to receive either 28 days (P28) or 40 days (P40) of sodium stibogluconate (Pentostam). Treatment was prematurely terminated due to thrombocytopenia in three patients and two patients did not complete six months of follow-up. At one month post-treatment, 13% (2 of 16) of the P28 patients and 16% (3 of 19) of the P40 patients no longer had infiltrates or ulcers and were initially considered cured. During a further 11 months of follow-up, infiltrated lesions healed in eight more P28 patients and in 10 more P40 patients. The cure rate after 12 months of follow-up was therefore 63% for both groups (10 of 16 in the P28 group and 12 of 19 in the P40 group). The total of 13 patients who had infiltrates or ulcers at the 9-12-month follow-up were considered failures. All seven patients (three in the P28 group and four in the P40 group) whose lesions were culture-positive for Leishmania at some point in the 12 months after treatment, and who were thereby parasitologic failures, were also clinical failures.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

PubMed1990

Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis.

OBJECTIVE: To determine the efficacy and toxicity of the World Health Organization's (WHO) recommended treatment for mucosal leishmaniasis: antimony, 20 mg/kg body weight per day for 28 days. DESIGN: Open trial with 12-month follow-up. SETTING: Inpatient unit of a regional referral hospital in a developing country. PATIENTS: Twenty-nine consecutive eligible patients with culture-confirmed infection of the mucosa with Leishmania species who were otherwise healthy. Eight patients (28%) had mild to moderate disease (confined to the nasal mucosa). Twenty-one patients (72%) had severe disease (including the oropharynx as well as the nasal mucosa). INTERVENTION: Antimony, 20 mg/kg body weight intravenously every day for 28 days. Patients received antimony in the form of sodium stibogluconate. MEASUREMENTS AND MAIN RESULTS: Initial results of therapy were as follows: 63 of 72 lesions (88%) healed or markedly improved; all lesions were culture-negative for parasites; and 18 of 29 patients (62%) showed complete clinical and parasitologic cure of all lesions. By the 12-month follow-up examinations, however, 37 lesions had recurred, 8 new lesions had appeared, and only 8 patients (30%) showed clinical cure of all lesions. Of the 8 patients with mild to moderate disease, 6 were cured compared with only 2 of the 21 patients with severe disease. Side effects of this treatment regimen included T-wave inversion on electrocardiogram (4 patients), abnormal liver function tests (10 patients), and musculoskeletal pain (24 patients). No side effects occurred during week 1 of therapy. CONCLUSIONS: The only recommended treatment for mucosal leishmaniasis is ineffective in patients with severe disease. The acceptable toxicity of the regimen suggests that longer courses of therapy with antimony, or that trials with other antileishmanial agents alone or combined with antimony be evaluated as initial therapy for this disease.

Adult↗

PubMed1990

Diffuse cutaneous leishmaniasis acquired in Peru.

A case of diffuse cutaneous leishmaniasis (DCL) acquired in Peru is described. The causative agent was Leishmania mexicana amazonensis as determined by isoenzyme analysis and species-specific monoclonal antibody binding characteristics. Histological examination of biopsy material showed a large number of intracellular and extracellular amastigotes and few lymphocytes. Treatment with meglumine antimoniate (Glucantime) administered iv at a dosage of 20 mg antimony/kg body weight/day for 60 days resulted in visible improvement of the lesions, but not in clinical or parasitological cure.

Adult↗